Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia

被引：0
|
作者：
Claudia Stefanutti
机构：
[1] “Sapienza” University of Rome,Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Regional Centre (Lazio) for Rare Diseases, Immunohematology and Transfusion Medicine, Department of Molecular Medicine
[2] “Umberto I” Hospital,undefined
来源：
Current Atherosclerosis Reports | 2020年 / 22卷
关键词：
Homozygous familial hypercholesterolemia; Lomitapide; Cardiovascular disease; Lipoprotein apheresis; Drug therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Lomitapide: a novel drug for homozygous familial hypercholesterolemia
    Panno, Maria D.
    Cefalu, Angelo B.
    Averna, Maurizio R.
    CLINICAL LIPIDOLOGY, 2014, 9 (01) : 19 - 32
  • [22] Lomitapide for treatment of homozygous familial hypercholesterolemia: The Quebec experience
    Aljenedil, Sumayah
    Alothman, Latifah
    Belanger, Alexandre M.
    Brown, Leslie
    Lahijanian, Zubin
    Bergeron, Jean
    Couture, Patrick
    Baass, Alexis
    Ruel, Isabelle
    Brisson, Diane
    Khoury, Etienne
    Gaudet, Daniel
    Genest, Jacques
    ATHEROSCLEROSIS, 2020, 310 : 54 - 63
  • [23] Sustained LDL-C Lowering and Stable Hepatic Fat Levels in Patients With Homozygous Familial Hypercholesterolemia Treated With the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide: Results of an Ongoing Long-Term Extension Study
    Cuchel, Marina
    Blom, Dirk J.
    Averna, Maurizio R.
    Meagher, Emma A.
    Theron, Hendrik D.
    Sirtori, Cesare R.
    Hegele, Robert A.
    Shah, Prediman K.
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni B.
    Bloedon, LeAnne T.
    Rader, Daniel J.
    CIRCULATION, 2013, 128 (22)
  • [24] US FDA approves lomitapide for homozygous familial hypercholesterolemia
    Wilson, Hannah
    CLINICAL LIPIDOLOGY, 2013, 8 (01) : 11 - 12
  • [25] Use of Microsomal Triglyceride Transfer Protein Inhibitors in Patients With Homozygous Familial Hypercholesterolemia: Translating Clinical Trial Experience Into Clinical Practice
    Toth, Peter P.
    Shah, Prediman K.
    Wilkinson, Michael J.
    Davidson, Michael H.
    McCullough, Peter A.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2014, 15 (01) : 1 - 10
  • [26] Lomitapide, relief pitcher for patients with homozygous familial hypercholesterolemia
    Kim, Sang-Hyun
    Baek, Sang Hong
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (02) : 155 - 156
  • [27] Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia
    Davis, Kyle A.
    Miyares, Marta A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (12) : 1001 - 1008
  • [28] Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide
    Giammanco, Antonina
    Cefalu, Angelo B.
    Noto, Davide
    Averna, Maurizio R.
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (23) : 3773 - 3783
  • [29] Lomitapide in homozygous familial hypercholesterolemia: our clinical experience
    Citta, D.
    Nota, F.
    Napoli, F.
    Frascaroli, C.
    Pisu, E.
    Massucco, P.
    Cavalot, F.
    Bonomo, K.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 131 - 131
  • [30] EFFICACY OF LOMITAPIDE ACROSS THE SPECTRUM OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Hegele, Robert A.
    Shah, Prediman K.
    DiGioia, Kenneth
    Jurecka, Agnieszka
    Blom, Dirk
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 149 - 149
12345